<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35235">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02012920</url>
  </required_header>
  <id_info>
    <org_study_id>VMT-VT-464-CL-001</org_study_id>
    <nct_id>NCT02012920</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer</brief_title>
  <official_title>A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT-464 in Patients With Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viamet Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viamet Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics
      and activity of VT-464, a lyase-selective inhibitor of CYP17,  in patients with
      castration-resistant prostate cancer (CRPC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2 study of VT-464 in treatment-naïve patients CRPC and CRPC patients who
      have failed prior therapy with abiraterone, enzalutamide, and/or chemotherapy.  The study
      consists of 2 phases: a dose-escalation phase (Phase 1) and a cohort-expansion phase (Phase
      2).  Phase 1 will be an open-label, multicenter, sequential-dose cohort design in
      treatment-naive patients and Phase 2 will be an open-label, multicenter, parallel-group
      design and treatment-naive and treatment-failure patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The safety and tolerability of VT-464 by evaluating adverse events, vital signs, physical examination findings, concomitant medications and laboratory tests.</measure>
    <time_frame>The first 28-day continuous dosing cycle at target dose.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetics of VT-464 using measures that include Cmax, Tmax and AUC</measure>
    <time_frame>The first 28-day continuous dosing cycle at target dose.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>The change in PSA from baseline using waterfall plots in response to VT-464</measure>
    <time_frame>At least monthly over the first 8 28-day dosing cycles</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Objective tumor response to VT-464 at the end of even-numbered cycles using RECIST 1.1 criteria</measure>
    <time_frame>At least every other month over the first 8 28-day dosing cycles</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>The absolute and percent change from baseline in adrenal, pituitary, and testicular hormone concentrations in response to VT-464</measure>
    <time_frame>At least monthly over the first 8 28-day dosing cycles</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">141</enrollment>
  <condition>Castration-resistant Prostate Cancer</condition>
  <condition>CRPC</condition>
  <arm_group>
    <arm_group_label>Treatment-Naive Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VT-464: given orally twice daily in 28 day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Previous abiraterone but chemo-naive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VT-464: given orally twice daily in 28 day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Previous enzalutamide but chemo-naive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VT-464: given orally twice daily in 28 day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Previous abiraterone, enzalutamide and/or chemo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VT-464: given orally twice daily in 28 day cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VT-464: given orally twice daily in 28 day cycles</intervention_name>
    <arm_group_label>Treatment-Naive Patients</arm_group_label>
    <arm_group_label>Previous abiraterone but chemo-naive</arm_group_label>
    <arm_group_label>Previous enzalutamide but chemo-naive</arm_group_label>
    <arm_group_label>Previous abiraterone, enzalutamide and/or chemo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Patients must have documented histological or cytological evidence of adenocarcinoma
             of the prostate.

          -  Patients must have a minimum serum PSA level of &gt;2 ng/ml that is rising based on the
             Prostate Cancer Working Group 2 criteria.

          -  Patients must have castrate levels of testosterone (&lt;50 ng/dl [1.74 nmol/l]).

          -  Patients must have undergone orchiectomy, or have been on LHRH agonists or
             antagonists, for at least 3 months prior to study entry.  Patients on LHRH
             agonists/antagonists must remain on these agents for the duration of the study.

          -  Patients must have an ECOG Performance Score of 0 or 1.

        Key Exclusion Criteria:

          -  Patients who have received prior cytotoxic chemotherapy for prostate cancer unless
             enrolled in a previous chemotherapy cohort.

          -  Patients who have received second-line antihormonal therapy, including ketoconazole,
             aminoglutethimide, or high-dose estrogen within 30 days of study entry.

          -  Patients who have completed sipuleucel-T (Provenge ®) treatment within 30 days of
             study entry.

          -  Patients who have received abiraterone (Zytiga®), TAK-700 (Orteronel®), TOK-001
             (Galeterone®), or MDV3100, or any other investigational product directed towards the
             androgen receptor or androgen biosynthesis. Previous abiraterone and enzalutamide are
             allowed in certain treatment-failure cohorts

          -  Patients who have received antiandrogens such as flutamide (EULEXIN®), bicalutamide
             (CASODEX®), or nilutamide (NILANDRON®) for &gt; 3 months must be off treatment for 6
             weeks and demonstrate  a continued rise in PSA after withdrawal.  Patients on
             antiandrogens for &lt; 3 months must be off medication for 2 weeks. Patients on 5 alpha
             reductase inhibitors such as finasteride (PROSCAR®, PROPECIA®), or dutasteride
             (AVODART®) must stop medication at least 3 months from study entry.

          -  Patients who require pharmacological or replacement doses of systemic corticosteroids
             or who have received systemic corticosteroids within 30 days of study entry; use of
             topical, inhaled or ophthalmic steroids is permitted.

          -  Patients who have received palliative radiotherapy within 4 weeks of study entry.

          -  Patients with a history within the last 3 years of another invasive malignancy.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Urology Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendie Philips, RN</last_name>
      <phone>402-991-8468</phone>
      <email>wphilips@gucancer.com</email>
    </contact>
    <investigator>
      <last_name>Luke Nordquist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>86169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Dios, RN</last_name>
      <phone>702-952-3400</phone>
      <email>Debbie.Dios@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Nicholas J Vogelzang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oscar Goodman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn McNeil, RN</last_name>
      <phone>919-684-1390</phone>
      <email>donna.mcneil@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of North Carolina</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Robinson, RN</last_name>
      <phone>919-510-5637</phone>
      <email>patricia.robinson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>William Berry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Griffith</last_name>
      <phone>843-449-1010</phone>
      <phone_ext>316</phone_ext>
      <email>jgriffith@atlanticurologyclinics.com</email>
    </contact>
    <investigator>
      <last_name>Neal Shore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Beth Storms, RN</last_name>
      <phone>713-563-7244</phone>
      <email>mstorms@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>John C Araujo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Simmons, B.A.</last_name>
      <phone>608-263-7107</phone>
      <email>kssimmons@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Glenn Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alexandria Hospital, Department of Oncology</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Revekka Gyftaki</last_name>
      <phone>+30 6937064958</phone>
      <email>rgyftaki@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eleni Efstathiou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St Gallen, Onkologie/ Hamatologie</name>
      <address>
        <city>St Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Meehan, RN</last_name>
      <email>Brian.Meehan@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Silke Gillessen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurelius Omlin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital - Institute of Cancer Research</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Smith, MD</last_name>
      <email>alan.smith@icr.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Johann De Bono, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alan Smith, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Greece</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>December 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>castration-resistant prostate cancer</keyword>
  <keyword>CYP17</keyword>
  <keyword>P450c17a</keyword>
  <keyword>lyase</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
